DACOPLICE 45MG TABLET
DACOMITINIB
Manufacturer : PFIZER LTDOrigin of Medicine : United States of AmericaBuy for 10 months, Get LIFETIME FREE. Contact us for latest updates.
Buy for 10 months, Get LIFETIME FREE. Contact us for latest updates.
Introduction:
Dacoplice 45mg Tablet is a anticancer medication containing the active constituent dacomitinib. It is used to treat a type of lung cancer called non-small cell lung cancer (NSCLC). Cancer is a condition in which cells multiply in an abnormal and uncontrolled manner. This medication is given when a test has shown that the NSCLC cancer has certain changes in a gene called EGFR and has spread to other parts of the body.
Dacoplice 45mg Tablet is not recommended for adolescents and children under 18 years of age. You need to inform your physician if you have any other lung problems before taking this medication. Use effective birth control during the treatment and for at least seventeen days after the last dose. Talk to the physician if you are intolerant to sugars before taking this medicine, as this medication contains lactose.
Do not take more tablets than recommended. Wear protective clothing and use sunscreen when you go outside during the treatment. Tell your doctor immediately if you experience diarrhea, skin rash, yellowing of skin or whites of eyes, dark-colored urine or light-colored stools while taking Dacoplice 45mg Tablet.
Dacoplice 45 mg uses:
- Non-small cell lung cancer (NSCLC)
How Dacoplice 45mg Tablet 30'S works:
Dacoplice 45mg Tablet works by blocking the action of a protein called EGFR, which is involved in the growth and spread of cancer cells.
Interactions with other drugs:
Inform your doctor about any medications you are taking or have taken before the treatment.
More information:
- Keep Dacoplice out of sight and reach of children.
- Store at 20°C to 25°C.
References:
- Pfizer Limited, Electronic medicines compendium (emc), [Revised on Jan 2021] [ Accessed on 2nd Dec 2021], https://www.medicines.org.uk/emc/files/pil.10354.pdf
- Pfizer Labs, US Food and Drug Administration, [Revised on Sept 2018] [ Accessed on 2nd Dec 2021], https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf
- Sally CM Lau et al; Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer; Drugs; Published on June 2019; Accessed on 02/12/2021; https://pubmed.ncbi.nlm.nih.gov/31069718/
How to use Dacoplice 45mg Tablet:
Take Dacoplice 45 mg in a dose and duration prescribed by your doctor. Swallow the tablets whole with water. Do not crush or chew the tablets. You can take these tablets with or without meals.
Safety advice:
Pregnancy:
Dacoplice 45mg Tablet should not be taken during pregnancy as it can harm the baby. You need to tell your physician if you are pregnant or planning to get pregnant before taking this medicine.
Breastfeeding:
Do not breastfeed while taking Dacoplice 45mg Tablet. You need to tell your physician if you are breastfeeding before taking this medicine.
Driving:
Dacoplice 45mg Tablet can cause tiredness and eye irritation. Avoid driving if you are unwell.
Others:
- You need to tell your health care professional if you have any other lung problems or intolerance to sugars before taking this medication.
- Wear protective clothing and use sunscreen when you go outside during the treatment.
Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them.
Serious:
- Lung inflammation (difficulty in breathing, cough, or fever)
- Diarrhea
- Skin rash
Common:
- Swelling of the lips and mouth
- Nail problems
- Dry skin
- Loss of appetite
- Hair loss
- Weight loss
- Nausea, vomiting
- Tiredness
- Flushed or painful soles or palms
- Dry, itchy, or red eyes

Want to know more?
Read Our Editorial Policy
4000+ products
We maintain strict quality controls on all our partner retailers, so that you always get standard quality products.

Secure Payment
100% secure and trusted payment protection

Easy Return
We have a new and dynamic return window policy for medicines and healthcare items. Refer FAQs section for more details.